Tscan Therapeutics is trading 5.7% higher at $0.20, alongside broader risk-on trading and biotech-sector strength. - No new company-specific announcement explaining the November 4 move was identified; its investor-relations page lists no release newer than October 6. - Nasdaq’s latest Tscan-specific news shown is dated September 4. Major U.S. indexes were sharply higher, while XBI gained 2.13%. - Nasdaq reported volume of 1,143 at 9:33 a.m. ET.